Back
Full-text
Journal article

Microbeam radiation therapy: Clinical perspectives.

  • Grotzer MA University Children's Hospital of Zurich, Steinwiesstrasse 75, CH-8032 Zurich, Switzerland. Electronic address: Michael.Grotzer@kispi.uzh.ch.
  • Schültke E Rostock University Medical Center, Department of Radiotherapy, Südring 75, 18059 Rostock, Germany.
  • Bräuer-Krisch E European Synchrotron Radiation Facility, 71 Avenue des Martyrs, F-38043 Grenoble Cedex 9, France.
  • Laissue JA University of Bern, Bern, Switzerland.
  • 2015-03-17
Published in:
  • Physica medica : PM : an international journal devoted to the applications of physics to medicine and biology : official journal of the Italian Association of Biomedical Physics (AIFB). - 2015
Brain tumour
Child
Diffuse intrinsic pontine glioma
Glioblastoma
Radiation therapy
Animals
Brain Neoplasms
Dose Fractionation, Radiation
Equipment Design
Evidence-Based Medicine
Humans
Mice
Radiotherapy, High-Energy
Rats
Swine
Synchrotrons
Technology Assessment, Biomedical
Treatment Outcome
English Microbeam radiation therapy (MRT), a novel form of spatially fractionated radiotherapy (RT), uses arrays of synchrotron-generated X-ray microbeams (MB). MRT has been identified as a promising treatment concept that might be applied to patients with malignant central nervous system (CNS) tumours for whom, at the current stage of development, no satisfactory therapy is available yet. Preclinical experimental studies have shown that the CNS of healthy rodents and piglets can tolerate much higher radiation doses delivered by spatially separated MBs than those delivered by a single, uninterrupted, macroscopically wide beam. High-dose, high-precision radiotherapies such as MRT with reduced probabilities of normal tissue complications offer prospects of improved therapeutic ratios, as extensively demonstrated by results of experiments published by many international groups in the last two decades. The significance of developing MRT as a new RT approach cannot be understated. Up to 50% of cancer patients receive conventional RT, and any new treatment that provides better tumour control whilst preserving healthy tissue is likely to significantly improve patient outcomes.
Language
  • English
Open access status
hybrid
Identifiers
Persistent URL
https://sonar.ch/global/documents/241471
Statistics
Document views: 57 File downloads:
  • Full-text: 0